Education
About Us
Working with TipRanks
Follow Us
Bio-Techne (TECH)
NASDAQ:TECH
Top Page
Bio-Techne
(NASDAQ:TECH)
Select Model
Select Model
Rating:64Neutral
Price Target:
$54.00
▲(5.43% Upside)
Bio-Techne's overall stock score reflects a stable financial position and strategic initiatives to improve profitability, as highlighted in the earnings call. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation. The company's ability to navigate market uncertainties and improve operational efficiencies will be crucial for future performance.
Positive Factors
Strong Cash Flow Generation
Bio-Techne's strong cash flow generation indicates efficient operations and provides the company with the flexibility to invest in growth opportunities and manage debt effectively, supporting long-term financial stability.
Strategic Divestiture
The divestiture allows Bio-Techne to focus on core growth areas and is expected to enhance operating margins by 200 basis points, improving profitability and strategic focus.
Growth in Biopharma Markets
Solid performance in biopharma markets, driven by large pharmaceutical customers, underscores Bio-Techne's strong market position and potential for sustained revenue growth in a key sector.
Negative Factors
Declining Profit Margins
Decreasing profit margins suggest operational challenges and rising costs, which could impact long-term profitability unless addressed through efficiency improvements.
Uncertain Biotech Funding Environment
The constrained funding environment for biotech firms may limit Bio-Techne's growth prospects and customer spending, posing a risk to revenue stability in the near to medium term.
Academia Segment Challenges
Challenges in the academia segment, due to uncertainties around funding, could hinder revenue growth and diversification, affecting Bio-Techne's performance in this important market.
Bio-Techne (TECH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.25B
Dividend Yield0.6%
Average Volume (3M)2.15M
Price to Earnings (P/E)115.5
Beta (1Y)0.90
Revenue Growth5.23%
EPS Growth-56.70%
CountryUS
Employees3,100
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.53
Shares Outstanding155,549,590
10 Day Avg. Volume2,556,556
30 Day Avg. Volume2,149,565
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue6.77
Enterprise Value/Gross Profit10.44
Enterprise Value/Ebitda36.99
Forecast
1Y Price Target
$66.00Price Target Upside28.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Bio-Techne Business Overview & Revenue Model
Company DescriptionBio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
How the Company Makes MoneyBio-Techne generates revenue through multiple streams, primarily from the sale of reagents, instruments, and diagnostic products. The Protein Platforms segment is a significant contributor to the company's earnings, as it provides essential research tools that are in high demand within the life sciences community. Additionally, the Diagnostics segment offers products that cater to the growing field of molecular diagnostics, contributing to recurring revenue from both product sales and potential partnerships with clinical laboratories. Bio-Techne also engages in strategic collaborations with other companies and research institutions, enhancing its market presence and expanding its product offerings, which further drives revenue. The company benefits from a strong customer base, including major pharmaceutical companies, which rely on Bio-Techne's products for drug development and testing.
Bio-Techne Key Performance Indicators (KPIs)
Any
Revenue by Geography
Data provided by:
Main Street Data
Main Street DataBio-Techne Earnings Call Summary
Earnings Call Date:Aug 06, 2025
(Q4-2025)
| % Change Since: |
Next Earnings Date:Nov 04, 2025
Earnings Call Sentiment Neutral
Bio-Techne's earnings call highlighted solid performance in the biopharma sector and strategic moves to enhance profitability, but also underscored challenges in academia and uncertainties in the biotech funding environment. The divestiture of Exosome Diagnostics is expected to improve margins, while potential tariff impacts and NIH funding uncertainties pose risks.Q4-2025 Updates
Positive Updates
Solid Quarterly Performance
Bio-Techne delivered 3% organic revenue growth in the fourth quarter of Fiscal Year 2025, driven by strong demand in the biopharma end markets, particularly among large pharma customers.
Profitability Focus
The company achieved an adjusted operating margin of 32% for the quarter, emphasizing operational efficiencies and a disciplined approach to investing for future growth.
Strategic Divestiture
Bio-Techne announced the divestiture of its Exosome Diagnostics business, expected to close in the first quarter of fiscal 2026, allowing the company to focus on its core growth pillars and improve operating margins.
Protein Sciences Segment Growth
The Protein Sciences segment grew 4% in the quarter with strong demand for proteomic analytical tools and cell therapy workflow solutions. The segment achieved a 5% revenue increase for the full fiscal year.
Geographic Performance
China delivered a positive surprise with low double-digit growth in the quarter, indicating stabilization and a gradual return to modest growth in the region.
Cell Therapy Solutions Demand
The demand for Bio-Techne's GMP reagents portfolio grew 20% in Q4 and exceeded 30% growth for the full fiscal year, supported by over 550 customers.
Negative Updates
Academia Segment Challenges
Revenue from academic customers declined low single digits in the fourth quarter, impacted by uncertainties around NIH funding and a softer biotech funding environment.
Diagnostics and Spatial Biology Segment Decline
Organic revenue for the Diagnostics and Spatial Biology segment declined 1% in the fourth quarter, primarily due to order timing across all three businesses and geopolitical headwinds affecting instrument placements.
Uncertain Biotech Funding Environment
Smaller biotech firms remained cautious with their spending amid a constrained funding environment, with biotech funding declining more than 40% year-to-date compared to 2024 levels.
Potential Pharmaceutical Tariffs and Drug Pricing Model Impact
The U.S. administration's commentary on potential pharmaceutical tariffs and a most favored nation drug pricing model introduced uncertainty across the pharma landscape.
Company Guidance
During Bio-Techne's fourth-quarter and fiscal year 2025 earnings call, the company reported a 3% organic revenue growth for the quarter and 5% for the full fiscal year, driven by strong performance in biopharma markets, particularly with large pharmaceutical customers. Approximately 80% of revenue came from consumables, supporting a resilient growth foundation. Despite uncertainties in the operating environment, Bio-Techne achieved an adjusted operating margin of 32% for the quarter. The company announced the divestiture of its Exosome Diagnostics business, expecting the transaction to close in the first quarter of fiscal 2026, which is anticipated to enhance their operating margin profile by 200 basis points. Looking forward, Bio-Techne anticipates maintaining low single-digit organic growth until market uncertainties resolve, while expecting around 100 basis points of adjusted operating margin expansion in fiscal 2026.Bio-Techne Financial Statement Overview
Summary
Bio-Techne shows a stable financial position with strong cash flow generation and prudent leverage. However, declining profitability margins and inconsistent revenue growth pose challenges. The company needs to address operational inefficiencies to improve overall financial performance.Income Statement
Bio-Techne's revenue growth has been inconsistent, with a significant drop in growth rate in the latest year. Gross profit margin remains strong, but net profit margin has decreased, indicating rising costs or inefficiencies. EBIT and EBITDA margins have also declined, suggesting pressure on operational profitability.65
Positive
Balance Sheet
The company maintains a healthy debt-to-equity ratio, indicating prudent leverage management. However, return on equity has decreased, reflecting lower profitability. The equity ratio is stable, showing a solid capital structure.72
Positive
Cash Flow
Operating cash flow remains robust, with a strong coverage ratio. Free cash flow growth is positive, though it has slowed down. The free cash flow to net income ratio is high, indicating efficient cash generation relative to earnings.78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.22B | 1.22B | 1.16B | 1.14B | 1.11B | 931.03M |
| Gross Profit | 790.27M | 790.27M | 769.73M | 769.82M | 756.50M | 632.85M |
| EBITDA | 223.07M | 216.88M | 310.37M | 460.56M | 420.12M | 258.47M |
| Net Income | 73.40M | 73.40M | 168.10M | 285.26M | 272.05M | 140.41M |
Balance Sheet | ||||||
| Total Assets | 2.56B | 2.56B | 2.70B | 2.64B | 2.29B | 2.26B |
| Cash, Cash Equivalents and Short-Term Investments | 162.19M | 162.19M | 152.86M | 204.31M | 247.03M | 231.55M |
| Total Debt | 444.06M | 444.06M | 419.54M | 454.96M | 325.97M | 420.55M |
| Total Liabilities | 639.06M | 639.06M | 635.02M | 672.18M | 593.79M | 691.72M |
| Stockholders Equity | 1.92B | 1.92B | 2.07B | 1.97B | 1.70B | 1.57B |
Cash Flow | ||||||
| Free Cash Flow | 256.55M | 256.55M | 236.10M | 216.15M | 280.36M | 307.86M |
| Operating Cash Flow | 287.56M | 287.56M | 298.98M | 254.39M | 325.27M | 352.16M |
| Investing Cash Flow | -35.18M | -35.18M | -203.03M | -265.65M | -96.85M | -243.52M |
| Financing Cash Flow | -253.91M | -253.91M | -122.40M | 22.62M | -242.85M | -62.55M |
Bio-Techne Technical Analysis
Negative
51.22
Price Trends
53.77
Negative
51.99
Negative
58.52
Negative
Market Momentum
-0.46
Positive
42.22
Neutral
42.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECH, the sentiment is Negative. The current price of 51.22 is below the 20-day moving average (MA) of 53.06, below the 50-day MA of 53.77, and below the 200-day MA of 58.52, indicating a bearish trend. The MACD of -0.46 indicates Positive momentum. The RSI at 42.22 is Neutral, neither overbought nor oversold. The STOCH value of 42.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TECH.
Bio-Techne Risk Analysis
Bio-Techne disclosed 27 risk factors in its most recent earnings report. Bio-Techne reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bio-Techne Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | 9.16B | 17.72 | 167.48% | ― | 34.97% | 71.10% | |
76 Outperform | 8.43B | 74.15 | 20.84% | ― | 25.71% | 4.48% | |
64 Neutral | 7.90B | -19.18 | -10.92% | ― | 4.52% | -205.13% | |
64 Neutral | $8.25B | 115.48 | 3.68% | 0.60% | 5.23% | -56.70% | |
61 Neutral | 10.20B | -21.09 | -11.29% | ― | -85.32% | -111.82% | |
55 Neutral | 6.58B | -32.70 | -137.04% | ― | 53.55% | 30.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
TECH
Bio-Techne
51.22
-26.42
-34.03%
CORT
Corcept Therapeutics
83.84
40.56
93.72%
HALO
Halozyme
75.64
18.69
32.82%
JAZZ
Jazz Pharmaceuticals
129.59
19.40
17.61%
RYTM
Rhythm Pharmaceuticals
96.91
45.78
89.54%
ROIV
Roivant Sciences
14.70
3.13
27.05%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.